OBJECTIVE: To determine if neurally adjusted ventilatory assist (NAVA) that delivers pressure in proportion to diaphragm electrical activity is as protective to acutely injured lungs (ALI) and non-pulmonary organs as volume controlled (VC), low tidal volume (Vt), high positive end-expiratory pressure (PEEP) ventilation. DESIGN: Prospective, randomized, laboratory animal study. SUBJECTS: Twenty-seven male New Zealand white rabbits. INTERVENTIONS: Anesthetized rabbits with hydrochloric acid-induced ALI were randomized (n = 9 per group) to 5.5 h NAVA (non-paralyzed), VC (paralyzed; Vt 6-ml/kg), or VC (paralyzed; Vt 15-ml/kg). PEEP was adjusted to hemodynamic goals in NAVA and VC6-ml/kg, and was 1 cmH2O in VC15-ml/kg. MEASUREMENTS AND MAIN RESULTS: PaO2/FiO2; lung wet-to-dry ratio; lung histology; interleukin-8 (IL-8) concentrations in broncho-alveolar-lavage (BAL) fluid, plasma, and non-pulmonary organs; plasminogen activator inhibitor type-1 and tissue factor in BAL fluid and plasma; non-pulmonary organ apoptosis rate; creatinine clearance; echocardiography. PEEP was similar in NAVA and VC6-ml/kg. During NAVA, Vt was lower (3.1 +/- 0.9 ml/kg), whereas PaO2/ FiO2, respiratory rate, and PaCO2 were higher compared to VC6-ml/kg (p<0.05 for all). Variables assessing ventilator-induced lung injury (VILI), IL-8 levels, non-pulmonary organ apoptosis rate, and kidney as well as cardiac performance were similar in NAVA compared to VC6-ml/kg. VILI and non-pulmonary organ dysfunction was attenuated in both groups compared to VC15-ml/kg. CONCLUSIONS: In anesthetized rabbits with early experimental ALI, NAVA is as effective as VC6-ml/kg in preventing VILI, in attenuating excessive systemic and remote organ inflammation, and in preserving cardiac and kidney function.
OBJECTIVE: To determine if neurally adjusted ventilatory assist (NAVA) that delivers pressure in proportion to diaphragm electrical activity is as protective to acutely injured lungs (ALI) and non-pulmonary organs as volume controlled (VC), low tidal volume (Vt), high positive end-expiratory pressure (PEEP) ventilation. DESIGN: Prospective, randomized, laboratory animal study. SUBJECTS: Twenty-seven male New Zealand white rabbits. INTERVENTIONS: Anesthetized rabbits with hydrochloric acid-induced ALI were randomized (n = 9 per group) to 5.5 h NAVA (non-paralyzed), VC (paralyzed; Vt 6-ml/kg), or VC (paralyzed; Vt 15-ml/kg). PEEP was adjusted to hemodynamic goals in NAVA and VC6-ml/kg, and was 1 cmH2O in VC15-ml/kg. MEASUREMENTS AND MAIN RESULTS:PaO2/FiO2; lung wet-to-dry ratio; lung histology; interleukin-8 (IL-8) concentrations in broncho-alveolar-lavage (BAL) fluid, plasma, and non-pulmonary organs; plasminogen activator inhibitor type-1 and tissue factor in BAL fluid and plasma; non-pulmonary organ apoptosis rate; creatinine clearance; echocardiography. PEEP was similar in NAVA and VC6-ml/kg. During NAVA, Vt was lower (3.1 +/- 0.9 ml/kg), whereas PaO2/ FiO2, respiratory rate, and PaCO2 were higher compared to VC6-ml/kg (p<0.05 for all). Variables assessing ventilator-induced lung injury (VILI), IL-8 levels, non-pulmonary organ apoptosis rate, and kidney as well as cardiac performance were similar in NAVA compared to VC6-ml/kg. VILI and non-pulmonary organ dysfunction was attenuated in both groups compared to VC15-ml/kg. CONCLUSIONS: In anesthetized rabbits with early experimental ALI, NAVA is as effective as VC6-ml/kg in preventing VILI, in attenuating excessive systemic and remote organ inflammation, and in preserving cardiac and kidney function.
Authors: James A Frank; Jorge A Gutierrez; Kirk D Jones; Lennell Allen; Leland Dobbs; Michael A Matthay Journal: Am J Respir Crit Care Med Date: 2002-01-15 Impact factor: 21.405
Authors: Christer Sinderby; Jennifer Beck; Jadranka Spahija; Michel de Marchie; Jacques Lacroix; Paolo Navalesi; Arthur S Slutsky Journal: Chest Date: 2007-03 Impact factor: 9.410
Authors: Ettore Crimi; Haibo Zhang; Robin N N Han; Lorenzo Del Sorbo; V Marco Ranieri; Arthur S Slutsky Journal: Am J Respir Crit Care Med Date: 2006-04-27 Impact factor: 21.405
Authors: V M Ranieri; P M Suter; C Tortorella; R De Tullio; J M Dayer; A Brienza; F Bruno; A S Slutsky Journal: JAMA Date: 1999-07-07 Impact factor: 56.272
Authors: Peter Dahlem; Albert P Bos; Jack J Haitsma; Marcus J Schultz; Joost C M Meijers; Burkhard Lachmann Journal: Intensive Care Med Date: 2005-03-08 Impact factor: 17.440
Authors: Jan Hirsch; Kirk C Hansen; Anil Sapru; James A Frank; Robert J Chalkley; Xiaohui Fang; Jonathan C Trinidad; Peter Baker; Alma L Burlingame; Michael A Matthay Journal: Am J Respir Crit Care Med Date: 2007-03-15 Impact factor: 21.405
Authors: Scott E Sinclair; David A Kregenow; Wayne J E Lamm; Ian R Starr; Emil Y Chi; Michael P Hlastala Journal: Am J Respir Crit Care Med Date: 2002-08-01 Impact factor: 21.405
Authors: Daniel Tuchscherer; Werner J Z'graggen; Christina Passath; Jukka Takala; Christer Sinderby; Lukas Brander Journal: Intensive Care Med Date: 2011-11-03 Impact factor: 17.440
Authors: Tommaso Mauri; Giacomo Bellani; Giuseppe Foti; Giacomo Grasselli; Antonio Pesenti Journal: Intensive Care Med Date: 2010-09-16 Impact factor: 17.440
Authors: Christian Karagiannidis; Matthias Lubnow; Alois Philipp; Guenter A J Riegger; Christof Schmid; Michael Pfeifer; Thomas Mueller Journal: Intensive Care Med Date: 2010-08-06 Impact factor: 17.440
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-02-23 Impact factor: 17.440